Human Lung Adenocarcinoma Cancer Associated Fibroblasts

Human Lung Adenocarcinoma Cancer-Associated Fibroblasts (hLUAD-CAFs) are primary stromal cells isolated directly from patient tumor specimens, representing the most abundant and functionally dominant non-malignant constituents of the lung adenocarcinoma tumor microenvironment (TME). Unlike immortalized fibroblast lines or animal xenografts, hLUAD-CAFs preserve patient-specific genetic and epigenetic landscapes, sustain native activated myofibroblast phenotypes, and authentically recapitulate the intricate paracrine signaling networks that govern tumor progression, extracellular matrix (ECM) desmoplasia, and therapeutic resistance.

These cells constitutively express established CAF markers—including α-SMA, FAP-α, vimentin, and PDGFR-β—while secreting a potent array of tumor-modulating mediators such as TGF-β1, IL-6, CXCL12/SDF-1, and matrix metalloproteinases. Through dynamic ECM remodeling and bidirectional crosstalk with malignant and immune compartments, hLUAD-CAFs actively promote cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition, immunosuppressive macrophage polarization, and regulatory T-cell recruitment. Contemporary single-cell transcriptomic analyses have further unveiled substantial inter-patient heterogeneity among hLUAD-CAF subpopulations, including myofibroblastic and inflammatory subsets, underscoring their indispensable value in personalized biomarker discovery, patient stratification, and subtype-specific therapeutic targeting.

As a physiologically relevant ex vivo platform, hLUAD-CAFs offer distinct and unparalleled experimental advantages: native secretory fidelity, superior translational predictability across diverse in vitro systems, and seamless compatibility with co-culture platforms, 3D organoid models, and high-throughput drug screening workflows. Moreover, their relative genetic stability compared to malignant cells renders them robust, druggable targets for mechanism-driven validation and stroma-directed therapeutic discovery.